Literature DB >> 28886202

Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.

V Vinod Mootha1,2, Brock Hansen1, Ziye Rong1, Pradeep P Mammen3, Zhengyang Zhou2, Chao Xing2,4,5, Xin Gong1.   

Abstract

Purpose: The most common cause of Fuchs' endothelial corneal dystrophy (FECD) is an intronic CTG repeat expansion in TCF4. Expanded CUG repeat RNA colocalize with splicing factor, muscleblind-like 1 (MBNL1), in nuclear foci in endothelium as a molecular hallmark. Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by a CTG repeat expansion in the 3'-untranslated region (UTR) of DMPK. In this study, we examine for RNA-MBNL1 foci in endothelial cells of FECD subjects with DM1, test the hypothesis that DM1 patients are at risk for FECD, and determine prevalence of TCF4 and DMPK expansions in a FECD cohort.
Methods: Using FISH, we examined for nuclear RNA-MBNL1 foci in endothelial cells from FECD subjects with DM1. We examined 13 consecutive unrelated DM1 patients for FECD using slit-lamp and specular microscopy. We genotyped TCF4 and DMPK repeat polymorphisms in a FECD cohort of 317 probands using short-tandem repeat and triplet repeat-primed PCR assays.
Results: We detected abundant nuclear RNA foci colocalizing with MBNL1 in endothelial cells of FECD subjects with DM1. Six of thirteen DM1 patients (46%) had slit-lamp and specular microscopic findings of FECD, compared to 4% disease prevalence (P = 5.5 × 10-6). As expected, 222 out of 317 (70%) FECD probands harbored TCF4 expansion, while one subject harbored DMPK expansion without prior diagnosis of DM1. Conclusions: Our work suggests that DM1 patients are at risk for FECD. DMPK mutations contribute to the genetic burden of FECD but are uncommon. We establish a connection between two repeat expansion disorders converging upon RNA-MBNL1 foci and FECD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28886202      PMCID: PMC5590687          DOI: 10.1167/iovs.17-22350

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  42 in total

1.  25 years dystrophia myotonica (D.M.).

Authors:  T A VOS
Journal:  Ophthalmologica       Date:  1961-01       Impact factor: 3.250

2.  Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions.

Authors:  M-E Arsenault; C Prévost; A Lescault; C Laberge; J Puymirat; J Mathieu
Journal:  Neurology       Date:  2006-04-25       Impact factor: 9.910

3.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts.

Authors:  B M Davis; M E McCurrach; K L Taneja; R H Singer; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

4.  Genetic association of TCF4 intronic polymorphisms, CTG18.1 and rs17089887, with Fuchs' endothelial corneal dystrophy in an Indian population.

Authors:  Gargi Gouranga Nanda; Biswajit Padhy; Sujata Samal; Sujata Das; Debasmita Pankaj Alone
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-10-23       Impact factor: 4.799

5.  Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy.

Authors:  S Biswas; F L Munier; J Yardley; N Hart-Holden; R Perveen; P Cousin; J E Sutphin; B Noble; M Batterbury; C Kielty; A Hackett; R Bonshek; A Ridgway; D McLeod; V C Sheffield; E M Stone; D F Schorderet; G C Black
Journal:  Hum Mol Genet       Date:  2001-10-01       Impact factor: 6.150

Review 6.  Structure and function of helix-loop-helix proteins.

Authors:  C Murre; G Bain; M A van Dijk; I Engel; B A Furnari; M E Massari; J R Matthews; M W Quong; R R Rivera; M H Stuiver
Journal:  Biochim Biophys Acta       Date:  1994-06-21

7.  Central cornea guttata. Incidence in the general population.

Authors:  D W Lorenzetti; M H Uotila; N Parikh; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1967-12       Impact factor: 5.258

8.  The role of apoptosis in the pathogenesis of Fuchs endothelial dystrophy of the cornea.

Authors:  Q J Li; M F Ashraf; D F Shen; W R Green; W J Stark; C C Chan; T P O'Brien
Journal:  Arch Ophthalmol       Date:  2001-11

9.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

10.  Fuchs endothelial corneal dystrophy in patients with myotonic dystrophy: a case series.

Authors:  Devin Gattey; Angela Y Zhu; Anna Stagner; Mark A Terry; Albert S Jun
Journal:  Cornea       Date:  2014-01       Impact factor: 2.651

View more
  17 in total

Review 1.  Repeat-associated RNA structure and aberrant splicing.

Authors:  Melissa A Hale; Nicholas E Johnson; J Andrew Berglund
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-16       Impact factor: 4.490

2.  Duplex RNAs and ss-siRNAs Block RNA Foci Associated with Fuchs' Endothelial Corneal Dystrophy.

Authors:  Jiaxin Hu; Xiulong Shen; Frank Rigo; Thahza P Prakash; V Vinod Mootha; David R Corey
Journal:  Nucleic Acid Ther       Date:  2019-01-24       Impact factor: 5.486

3.  Instability of TCF4 Triplet Repeat Expansion With Parent-Child Transmission in Fuchs' Endothelial Corneal Dystrophy.

Authors:  Joanna S Saade; Chao Xing; Xin Gong; Zhengyang Zhou; V Vinod Mootha
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-08-01       Impact factor: 4.799

4.  Delivery of Antisense Oligonucleotides to the Cornea.

Authors:  Viet Q Chau; Jiaxin Hu; Xin Gong; John D Hulleman; Rafael L Ufret-Vincenty; Frank Rigo; Thahza P Prakash; David R Corey; V Vinod Mootha
Journal:  Nucleic Acid Ther       Date:  2020-03-23       Impact factor: 5.486

5.  Oligonucleotides targeting TCF4 triplet repeat expansion inhibit RNA foci and mis-splicing in Fuchs' dystrophy.

Authors:  Jiaxin Hu; Ziye Rong; Xin Gong; Zhengyang Zhou; Vivek K Sharma; Chao Xing; Jonathan K Watts; David R Corey; V Vinod Mootha
Journal:  Hum Mol Genet       Date:  2018-03-15       Impact factor: 6.150

6.  Antisense Therapy for a Common Corneal Dystrophy Ameliorates TCF4 Repeat Expansion-Mediated Toxicity.

Authors:  Christina Zarouchlioti; Beatriz Sanchez-Pintado; Nathaniel J Hafford Tear; Pontus Klein; Petra Liskova; Kalyan Dulla; Ma'ayan Semo; Anthony A Vugler; Kirithika Muthusamy; Lubica Dudakova; Hannah J Levis; Pavlina Skalicka; Pirro Hysi; Michael E Cheetham; Stephen J Tuft; Peter Adamson; Alison J Hardcastle; Alice E Davidson
Journal:  Am J Hum Genet       Date:  2018-03-08       Impact factor: 11.025

7.  Fuchs' Endothelial Corneal Dystrophy in Patients With Myotonic Dystrophy, Type 1.

Authors:  Nelson S Winkler; Margherita Milone; Jennifer M Martinez-Thompson; Harish Raja; Ross A Aleff; Sanjay V Patel; Michael P Fautsch; Eric D Wieben; Keith H Baratz
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

Review 8.  Fuchs endothelial corneal dystrophy: The vicious cycle of Fuchs pathogenesis.

Authors:  Stephan Ong Tone; Viridiana Kocaba; Myriam Böhm; Adam Wylegala; Tomas L White; Ula V Jurkunas
Journal:  Prog Retin Eye Res       Date:  2020-05-08       Impact factor: 21.198

9.  Analyzing pre-symptomatic tissue to gain insights into the molecular and mechanistic origins of late-onset degenerative trinucleotide repeat disease.

Authors:  Yongjun Chu; Jiaxin Hu; Hanquan Liang; Mohammed Kanchwala; Chao Xing; Walter Beebe; C Bradley Bowman; Xin Gong; David R Corey; V Vinod Mootha
Journal:  Nucleic Acids Res       Date:  2020-07-09       Impact factor: 16.971

10.  Zebrafish mbnl mutants model physical and molecular phenotypes of myotonic dystrophy.

Authors:  Melissa N Hinman; Jared I Richardson; Rose A Sockol; Eliza D Aronson; Sarah J Stednitz; Katrina N Murray; J Andrew Berglund; Karen Guillemin
Journal:  Dis Model Mech       Date:  2021-06-14       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.